Bank of America Cites Zoetis Inc.’s (ZTS) Strong Q4 Performance and Fiscal 2026 Outlook

Zoetis Inc. (NYSE:ZTS) tops our database for being 1 of the cheap pharmaceutical stocks.

TheFly reported connected February 13 that Bank of America raised its terms people for ZTS to $140 from $135 and maintained a Neutral standing connected the shares. The upgraded people was supported by the company's fiscal 2026 projection and fourth-quarter performance, which were mostly successful enactment with expectations.

Zoetis Inc. (NYSE:ZTS) released its fourth-quarter 2025 fiscal results earlier connected February 12 and reported that adjusted EPS of $1.48 was higher than the $1.40 statement forecast. The institution besides reported that with a 3% year-over-year summation to $2.4 billion, the quarter's income showed beardown maturation successful some the U.S. and planetary regions.

The corp provided projections for fiscal twelvemonth 2026 arsenic good and predicted gross of $9.83 cardinal to $10.03 cardinal and adjusted EPS of $7.00 to $7.10, surpassing expert forecasts. Global operational gains, maturation successful important parasiticide and dermatology portfolios, and ongoing momentum successful companion carnal and cattle goods each enactment the expectation. These outcomes show ZTS's capableness to nutrient dependable maturation and solidify its lasting arsenic a satellite person successful carnal health.

Zoetis Inc. (NYSE:ZTS) is simply a planetary carnal wellness institution specializing successful medicines, vaccines, and diagnostic products for livestock and companion animals, aiming to heighten carnal health, productivity, and well-being worldwide.

While we admit the imaginable of ZTS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.